Trabectedin overcomes doxorubicin-resistance, counteracts tumor-immunosuppressive reprogramming of monocytes and decreases xenograft growth in Hodgkin lymphoma
Naike Casagrande, Cinzia Borghese, Andrea Favero, Cristina Vicenzetto, Donatella Aldinucci
Topics & Concepts
Cancer researchDoxorubicinLymphomaReprogrammingHodgkin lymphomaMedicineTrabectedinChemotherapyImmunologySarcomaChemistryPathologyInternal medicineCellBiochemistrySoft tissue sarcomaImmune cells in cancerCancer, Hypoxia, and MetabolismLymphoma Diagnosis and Treatment